- Lobbying
- Lobbying by UroGen Pharma, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Bob Wood | Chief of Staff to HHS Secretary See prior filing Chief of Staff to HHS Secretary; Intern to Rep. Scott Klug |
Remy Brim | Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren See prior filing Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz |
Dan Farmer | St. Asst Rep. Debbie Wasserman Schultz; Leg. Corr. Rep. Debbie Wasserman Schultz; Leg. Corr./Leg. Asst. Rep. Debbie Wasserman Schultz; Leg. Asst. Rep. Zack Space; Sr. Leg. Asst. Rep. Zack Space; Leg. Dir. Zack Space See prior filing Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space |
Robb Walton | Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Healthcare Aide Sen. Enzi Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Healthcare Aide Sen. Enzi See prior filing Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Provide strategic counsel and advocacy for issues related to cancer and urologic disease treatments and regulatory reimbursement policy around requirement for manufacturers to provide refunds to Medicare for discarded amounts..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate